Follow us on 
or join ours 
The small capital company Agenus Inc. intends to raise $ 50 million to $ 100 million by issuing digital assets backed by planned sales of an experimental anti-cancer drug. This is a completely innovative approach when it comes to the biotechnology industry.
Agenus and innovative biotechnology security tokens
As the company promises, digital assets will enable investment in the future sale of individual products, while exerting limited influence on shareholders. The company intends to offer its innovative, biotechnology security tokens (referred to by the company as BESTs) with a value of at least 25 million dollars. General manager of the company, Garo Armen, he argues that thanks to this type of innovative solutions, it is possible to submit a presentation much more focused on a specific product.
American company Agenus concentrating on immuno-oncological treatment, and is currently conducting clinical trials of the drug for cervical cancer, which can be approved already in the 2021 year. The digital offer, however, carries a certain degree of risk. First, to start generating income, the drug must be approved by securities regulators. Although the company's representatives ensure that the offer complies with the regulations of the Securities and Exchange Commission of the United States (SEC), it has not been finally approved by the Commission. This, according to Armen, takes place within a few months.
According to experts, the offer will help accelerate the development of an anti-cancer drug, although it may prove slightly dilutive for the shareholders themselves. At the same time, the management of Agenus ensures that the BESTs offer has nothing to do with cryptocurrencies, and the company does not currently participate in the cryptography market. Moreover, the company plans to take appropriate measures to protect investors if the drug is not allowed to circulate.
tokens companies are based on technology blockchain enabling verification and registration of transactions. Agenus acquires funds through a digital investment group Atomic Capital. Group representatives say that more and more biotechnology companies are turning towards digital financial methods.
